[1]
|
Süudhof, T.C. (2008) Pharmacology of Neurotransmitter Release. Handbook of Experimental Pharmacology. Springer, Berlin, 1-21. https://doi.org/10.1007/978-3-540-74805-2_1
|
[2]
|
Guillot, T.S. and Miller, G.W. (2009) Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons. Molecular Neurobiology, 39, 149-170. https://doi.org/10.1007/s12035-009-8059-y
|
[3]
|
Li, N. and Jasanoff, A. (2020) Local and Global Consequences of Reward-Evoked Striatal Dopamine Release. Nature, 580, 239-244. https://doi.org/10.1038/s41586-020-2158-3
|
[4]
|
Björklund, A. and Dunnett, S.B. (2007) Dopamine Neuron Sys-tems in the Brain: An Update. Trends in Neurosciences, 30, 194-202. https://doi.org/10.1016/j.tins.2007.03.006
|
[5]
|
Dackis, C.A. and Gold, M.S. (1985) New Concepts in Cocaine Addiction: The Dopamine Depletion Hypothesis. Neuroscience and Biobehavioral Reviews, 9, 469-477. https://doi.org/10.1016/0149-7634(85)90022-3
|
[6]
|
Berridge, K.C. (2007) The Debate over Dopamine’s Role in Reward: The Case for Incentive Salience. Psychopharmacology (Berlin), 191, 391-431. https://doi.org/10.1007/s00213-006-0578-x
|
[7]
|
Chinta, S.J. and Andersen, J.K. (2005) Dopaminergic Neurons. The International Journal of Biochemistry & Cell Biology, 37, 942-946. https://doi.org/10.1016/j.biocel.2004.09.009
|
[8]
|
Beaulieu, J.M. and Gainetdinov, R.R. (2011) The Physiology, Signaling, and Pharmacology of Dopamine Receptors. Pharmacological Reviews, 63, 182-217. https://doi.org/10.1124/pr.110.002642
|
[9]
|
Missale, C., Nash, S.R., Robinson, S.W., et al. (1998) Dopamine Re-ceptors: From Structure to Function. Physiological Reviews, 78, 189-225. https://doi.org/10.1152/physrev.1998.78.1.189
|
[10]
|
Beaulieu, J.M., Espinoza, S. and Gainetdinov, R.R. (2015) Dopamine Receptors—IUPHAR Review 13. British Journal of Pharmacology, 172, 1-23. https://doi.org/10.1111/bph.12906
|
[11]
|
Latif, S., Jahangeer, M., Maknoon Razia, D., et al. (2021) Dopamine in Parkinson’s Disease. Clinica Chimica Ccta: International Journal of Clinical Chemistry, 522, 114-126. https://doi.org/10.1016/j.cca.2021.08.009
|
[12]
|
Gurevich, E.V., Gainetdinov, R.R. and Gurevich, V.V. (2016) G Protein-Coupled Receptor Kinases as Regulators of Dopamine Receptor Functions. Pharmacological Research, 111, 1-16. https://doi.org/10.1016/j.phrs.2016.05.010
|
[13]
|
Ford, C.P. (2014) The Role of D2-Autoreceptors in Regu-lating Dopamine Neuron Activity and Transmission. Neuroscience, 282, 13-22. https://doi.org/10.1016/j.neuroscience.2014.01.025
|
[14]
|
Lacey, M.G., Mercuri, N.B. and North, R.A. (1989) Two Cell Types in Rat Substantia Nigra Zona Compacta Distinguished by Membrane Properties and the Actions of Dopamine and Opioids. Journal of Neuroscience, 9, 1233-1241.
https://doi.org/10.1523/JNEUROSCI.09-04-01233.1989
|
[15]
|
Jones, S. and Kauer, J.A. (1999) Amphetamine De-presses Excitatory Synaptic Transmission via Serotonin Receptors in the Ventral Tegmental Area. The Journal of Neuroscience: The Official Journal of the Society, 19, 9780-9787.
https://doi.org/10.1523/JNEUROSCI.19-22-09780.1999
|
[16]
|
Benarroch, E.E. (2013) HCN Channels: Function and Clinical Implications. Neurology, 80, 304-310.
https://doi.org/10.1212/WNL.0b013e31827dec42
|
[17]
|
He, C., Chen, F., Li, B., et al. (2014) Neurophysiology of HCN Channels: From Cellular Functions to Multiple Regulations. Progress in Neurobiology, 112, 1-23. https://doi.org/10.1016/j.pneurobio.2013.10.001
|
[18]
|
Yamagata, N., Ichinose, T., Aso, Y., et al. (2015) Distinct Dopamine Neurons Mediate Reward Signals for Short- and Long-Term Memories. Proceedings of the National Academy of Sciences of the United States of America, 112, 578-583. https://doi.org/10.1073/pnas.1421930112
|
[19]
|
Popescu, A.T., Zhou, M.R. and Poo, M.M. (2016) Phasic Dopamine Release in the Medial Prefrontal Cortex Enhances Stimulus Discrimination. Proceedings of the National Academy of Sciences of the United States of America, 113, E3169-E3176. https://doi.org/10.1073/pnas.1606098113
|
[20]
|
Nestler, E.J. and Carlezon, W.A. (2006) The Mesolimbic Dopamine Reward Circuit in Depression. Biological Psychiatry, 59, 1151-1159. https://doi.org/10.1016/j.biopsych.2005.09.018
|
[21]
|
Haber, S.N. and Knutson, B. (2010) The Reward Circuit: Linking Primate Anatomy and Human Imaging. Neuropsychopharmacology, 35, 4-26. https://doi.org/10.1038/npp.2009.129
|
[22]
|
Oliva, I. and Wanat, M.J. (2016) Ventral Tegmental Area Afferents and Drug-Dependent Behaviors. Frontiers in Psychiatry, 7, Article No. 30. https://doi.org/10.3389/fpsyt.2016.00030
|
[23]
|
Margolis, E.B., Lock, H., Hjelmstad, G.O., et al. (2006) The Ventral Tegmental Area Revisited: Is There an Electrophysiological Marker for Dopaminergic Neurons? The Journal of Physiology, 577, 907-924.
https://doi.org/10.1113/jphysiol.2006.117069
|
[24]
|
Margolis, E.B., Toy, B., Himmels, P., et al. (2012) Identification of Rat Ventral Tegmental Area GABAergic Neurons. PLOS ONE, 7, e42365. https://doi.org/10.1371/journal.pone.0042365
|
[25]
|
Nair-Roberts, R.G., Chatelain-Badie, S.D., Benson, E., et al. (2008) Stereological Estimates of Dopaminergic, GABAergic and Glutamatergic Neurons in the Ventral Tegmental Area, Substantia Nigra and Retrorubral Field in the Rat. Neuroscience, 152, 1024-1031. https://doi.org/10.1016/j.neuroscience.2008.01.046
|
[26]
|
Xin, W., Edwards, N. and Bonci, A. (2016) VTA Dopa-mine Neuron Plasticity—The Unusual Suspects. The European Journal of Neuroscience, 44, 2975-2983. https://doi.org/10.1111/ejn.13425
|
[27]
|
Trist, B.G., Hare, D.J. and Double, K.L. (2019) Oxidative Stress in the Aging Substantia Nigra and the Etiology of Parkinson’s Disease. Aging Cell, 18, e13031. https://doi.org/10.1111/acel.13031
|
[28]
|
Wakabayashi, K., Tanji, K., Odagiri, S., et al. (2013) The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders. Molecular Neurobiology, 47, 495-508. https://doi.org/10.1007/s12035-012-8280-y
|
[29]
|
Spillantini, M.G., Schmidt, M.L., Lee, V.M., et al. (1997) Al-pha-Synuclein in Lewy Bodies. Nature, 388, 839-840.
https://doi.org/10.1038/42166
|
[30]
|
Barrett, P.J. and Timothy, G.J. (2015) Post-Translational Modification of Al-pha-Synuclein in Parkinson’s Disease. Brain Research, 1628, 247-253. https://doi.org/10.1016/j.brainres.2015.06.002
|
[31]
|
Polymeropoulos, M.H., Lavedan, C., Leroy, E., et al. (1997) Mutation in the Alpha-Synuclein Gene Identified in Families with Parkinson’s Disease. Science, 276, 2045-2047. https://doi.org/10.1126/science.276.5321.2045
|
[32]
|
Collaborators, G.N. (2019) Global, Regional, and National Burden of Neurological Disorders, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18, 459-480.
https://doi.org/10.1016/S1474-4422(18)30499-X
|
[33]
|
Balestrino, R. and Schapira, A.H.V. (2020) Parkinson Dis-ease. European Journal of Neurology, 27, 27-42.
https://doi.org/10.1111/ene.14108
|
[34]
|
Beitz, J.M. (2014) Parkinson’s Disease: A Review. Frontiers in Bioscience, 6, 65-74. https://doi.org/10.2741/S415
|
[35]
|
Tysnes, O.B. and Storstein, A. (2017) Epidemiology of Parkinson’s Disease. Journal of Neural Transmission, 124, 901-905. https://doi.org/10.1007/s00702-017-1686-y
|
[36]
|
Cerri, S., Mus, L. and Blandini, F. (2019) Parkinson’s Disease in Women and Men: What’s the Difference? Journal of Parkinson’s Disease, 9, 501-515. https://doi.org/10.3233/JPD-191683
|
[37]
|
Schapira, A.H. and Jenner, P. (2011) Etiology and Pathogenesis of Parkinson’s Disease. Movement Disorders, 26, 1049-1055. https://doi.org/10.1002/mds.23732
|
[38]
|
Bastide, M.F., Meissner, W.G., Picconi, B., et al. (2015) Pathophysiology of L-Dopa-Induced Motor and Non-Motor Complications in Parkinson’s Disease. Progress in Neurobiology, 132, 96-168.
https://doi.org/10.1016/j.pneurobio.2015.07.002
|